Short‐term Oral Steroids Significantly Improves Chronic Rhinosinusitis Without Nasal Polyps. (4th March 2021)

• Record Type: Journal Article
• Authors: De Silva, April P.; Schembri, Mark A.; Sarah, Angus H.; Chao, Jessica; Yip, Kwok Ho; Cildir, Gökhan; Lopez, Angel; Tumes, Damon J.; Pant, Harshita
• Is Part Of: Laryngoscope. Volume 131:Number 10(2021)
• Page Start: E2618
• Page End: E2626
• Publication Date: 2021-03-04
• Subjects: Chronic rhinosinusitis -- nasal polyps -- prednisolone -- steroids -- corticosteroids -- maximum medical therapy; Otolaryngology -- Periodicals; 617.51005
• DOI: 10.1002/lary.29495
• Languages: English
• ISSNs: 0023-852X

Abstract

Abstract : Objectives/Hypothesis: The efficacy of short‐term oral corticosteroids in chronic rhinosinusitis without nasal polyps (CRSsNP) is unknown. The aim of this controlled study was to assess the immediate and long‐term outcomes from a short course of a commonly used oral corticosteroid, prednisolone, in well‐defined CRSsNP patients. Study Design: Prospective, observational controlled study. Methods: A prospective‐controlled study of CRSsNP patients treated with prednisolone at 0.5 mg/kg tapered over 10 days and non‐prednisolone treated CRSsNP patients (controls) and follow‐up at 2, 6, and 12 months. Baseline and follow‐up SinoNasal Outcome Test (SNOT)‐22, nasal endoscopy (Lund‐Kennedy), and sinus CT scan scores (Lund‐Mackay) were compared. Results: At 2 months, there was a significant improvement in the SNOT‐22, nasal endoscopy, and sinus CT scan scores in the prednisolone group ( P < .0001) compared with controls (p = ns, Mann–Whitney U test). 52.5% of prednisolone‐treated CRSsNP patients had improved symptoms and did not require sinus surgery at 12 months compared with 14.3% of controls ( P < .001). Side‐effects were reported in 8.9% of prednisolone‐treated patients. Patients who benefited from prednisolone had a median symptom duration of 7.25 (99% confidence, upper limit of 11) months compared with 18 months in those requiring surgery. Conclusions: Short‐term oral prednisolone significantly improved all three clinical measures of disease in CRSsNP patients and avoided surgical intervention in 52.5% patients in the first 12 months. Patients with symptoms for less than 11 months were most likely to benefit. The side‐effects of oral steroids require careful consideration and further studies are needed to ascertain appropriate dosage and treatment duration. Level of Evidence: 3 Laryngoscope, 131:E2618–E2626, 2021